| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
11,100 |
8,990 |
$1.39M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
11,440 |
8,682 |
$1.25M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
10,507 |
7,355 |
$979K |
| 41899 |
Unlisted procedure, dentoalveolar structures |
298 |
239 |
$612K |
| 71045 |
Radiologic examination, chest; single view |
3,141 |
2,483 |
$302K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
4,675 |
3,484 |
$220K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
1,994 |
1,610 |
$144K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
20,988 |
15,485 |
$96K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
2,967 |
2,367 |
$75K |
| 80053 |
Comprehensive metabolic panel |
11,877 |
9,162 |
$63K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
2,407 |
1,799 |
$62K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
517 |
449 |
$48K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
925 |
735 |
$40K |
| 70450 |
Computed tomography, head or brain; without contrast material |
415 |
352 |
$35K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
630 |
108 |
$35K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
336 |
288 |
$28K |
| 71046 |
Radiologic examination, chest; 2 views |
202 |
161 |
$24K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
627 |
542 |
$23K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
150 |
131 |
$23K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
58 |
54 |
$20K |
| 36415 |
Collection of venous blood by venipuncture |
5,579 |
3,322 |
$19K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
689 |
482 |
$18K |
| 84484 |
|
2,857 |
1,729 |
$15K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
2,822 |
2,169 |
$12K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
122 |
114 |
$11K |
| G0378 |
Hospital observation service, per hour |
175 |
101 |
$10K |
| 64493 |
|
14 |
12 |
$9K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
1,094 |
843 |
$8K |
| 87070 |
|
1,093 |
992 |
$8K |
| 83605 |
|
1,418 |
1,074 |
$7K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
26 |
15 |
$6K |
| 84145 |
|
418 |
315 |
$5K |
| 83735 |
|
1,757 |
1,324 |
$5K |
| 84443 |
Thyroid stimulating hormone (TSH) |
471 |
395 |
$4K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
168 |
154 |
$4K |
| 83690 |
|
1,153 |
904 |
$3K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
16 |
14 |
$3K |
| 80061 |
Lipid panel |
370 |
317 |
$3K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
66 |
61 |
$3K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
143 |
95 |
$2K |
| 81001 |
|
1,474 |
1,172 |
$2K |
| 81025 |
|
412 |
356 |
$2K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
99 |
78 |
$2K |
| 81003 |
|
1,706 |
1,456 |
$2K |
| 82150 |
|
380 |
304 |
$1K |
| 83880 |
|
79 |
68 |
$1K |
| Q3014 |
Telehealth originating site facility fee |
18 |
18 |
$931.97 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
27 |
27 |
$912.34 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
27 |
27 |
$912.34 |
| 82550 |
|
305 |
216 |
$789.81 |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
132 |
30 |
$783.66 |
| 82553 |
|
256 |
199 |
$763.87 |
| 80076 |
|
108 |
90 |
$614.10 |
| 85379 |
|
115 |
94 |
$581.97 |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
38 |
37 |
$567.00 |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
71 |
57 |
$561.33 |
| 87088 |
|
108 |
86 |
$523.84 |
| 87040 |
|
164 |
63 |
$418.59 |
| 94664 |
|
57 |
32 |
$375.17 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
47 |
37 |
$223.33 |
| 85610 |
|
170 |
110 |
$200.12 |
| 87210 |
|
35 |
33 |
$174.59 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
20 |
12 |
$174.34 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
25 |
15 |
$158.30 |
| 84100 |
|
71 |
51 |
$146.59 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
17 |
14 |
$143.96 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
217 |
182 |
$130.50 |
| 84439 |
|
18 |
14 |
$90.20 |
| 84703 |
|
13 |
12 |
$72.90 |
| J2920 |
Injection, methylprednisolone sodium succinate, up to 40 mg |
30 |
24 |
$58.48 |
| 87077 |
|
57 |
24 |
$33.82 |
| J2795 |
Injection, ropivacaine hydrochloride, 1 mg |
106 |
64 |
$0.80 |
| J2704 |
Injection, propofol, 10 mg |
119 |
74 |
$0.00 |
| 97802 |
|
17 |
13 |
$0.00 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
395 |
292 |
$0.00 |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
18 |
14 |
$0.00 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
116 |
74 |
$0.00 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
40 |
39 |
$0.00 |
| J0595 |
Injection, butorphanol tartrate, 1 mg |
119 |
74 |
$0.00 |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
56 |
37 |
$0.00 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
130 |
92 |
$0.00 |
| 87186 |
|
17 |
12 |
$0.00 |
| 00170 |
Anesthesia for intraoral procedures, including biopsy |
26 |
12 |
$0.00 |